Immune regulatory adjuvant approach to mitigate subcutaneous immunogenicity of monoclonal antibodies.

ABSTRACT:

Introduction

Immunogenicity continues to be a challenge for development and clinical utility of monoclonal antibodies, and there are gaps in our current ability to prevent anti-drug antibody development in a safe and antigen-specific manner.

Methods

To mitigate immunogenicity of monoclonal antibodies administered subcutaneously, O-phospho-L-serine (OPLS)-the head group of the tolerance-inducing phospholipid, phosphatidylserine-was investigated as an immunoregulatory adjuvant.

Results

Formulations of adalimumab, trastuzumab or rituximab with OPLS showed reduction in relative immunogenicity in mice compared to vehicle formulations, indicated by reduced anti-drug antibody development and significant reductions in CD138+ plasma cell differentiation in bone marrow. Titer d

SUBMITTER: Jarvi NL 

PROVIDER: S-EPMC11666448 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature